Ignite Creation Date:
2025-12-24 @ 4:25 PM
Ignite Modification Date:
2025-12-28 @ 7:34 PM
Study NCT ID:
NCT00716066
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-16
First Post:
2008-07-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D020274', 'term': 'Autoimmune Diseases of the Nervous System'}, {'id': 'D016750', 'term': 'Stiff-Person Syndrome'}, {'id': 'D020293', 'term': 'Vasculitis, Central Nervous System'}, {'id': 'D020277', 'term': 'Polyradiculoneuropathy, Chronic Inflammatory Demyelinating'}, {'id': 'D015624', 'term': 'Lambert-Eaton Myasthenic Syndrome'}, {'id': 'D009157', 'term': 'Myasthenia Gravis'}, {'id': 'D009471', 'term': 'Neuromyelitis Optica'}, {'id': 'D053578', 'term': 'Opsoclonus-Myoclonus Syndrome'}, {'id': 'C535291', 'term': 'Rasmussen subacute encephalitis'}], 'ancestors': [{'id': 'D007154', 'term': 'Immune System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}, {'id': 'D013118', 'term': 'Spinal Cord Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009468', 'term': 'Neuromuscular Diseases'}, {'id': 'D002561', 'term': 'Cerebrovascular Disorders'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D014652', 'term': 'Vascular Diseases'}, {'id': 'D002318', 'term': 'Cardiovascular Diseases'}, {'id': 'D014657', 'term': 'Vasculitis'}, {'id': 'D011129', 'term': 'Polyradiculoneuropathy'}, {'id': 'D003711', 'term': 'Demyelinating Diseases'}, {'id': 'D011115', 'term': 'Polyneuropathies'}, {'id': 'D010523', 'term': 'Peripheral Nervous System Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D020361', 'term': 'Paraneoplastic Syndromes, Nervous System'}, {'id': 'D009423', 'term': 'Nervous System Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D010257', 'term': 'Paraneoplastic Syndromes'}, {'id': 'D019636', 'term': 'Neurodegenerative Diseases'}, {'id': 'D020511', 'term': 'Neuromuscular Junction Diseases'}, {'id': 'D009188', 'term': 'Myelitis, Transverse'}, {'id': 'D020278', 'term': 'Demyelinating Autoimmune Diseases, CNS'}, {'id': 'D009902', 'term': 'Optic Neuritis'}, {'id': 'D009901', 'term': 'Optic Nerve Diseases'}, {'id': 'D003389', 'term': 'Cranial Nerve Diseases'}, {'id': 'D005128', 'term': 'Eye Diseases'}, {'id': 'D015835', 'term': 'Ocular Motility Disorders'}, {'id': 'D009207', 'term': 'Myoclonus'}, {'id': 'D020820', 'term': 'Dyskinesias'}, {'id': 'D009461', 'term': 'Neurologic Manifestations'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D000961', 'term': 'Antilymphocyte Serum'}, {'id': 'C512542', 'term': 'thymoglobulin'}, {'id': 'D002330', 'term': 'Carmustine'}, {'id': 'C574855', 'term': 'carmustine, poliferprosan 20 drug combination'}, {'id': 'D003561', 'term': 'Cytarabine'}, {'id': 'D005047', 'term': 'Etoposide'}, {'id': 'D008558', 'term': 'Melphalan'}, {'id': 'D036102', 'term': 'Peripheral Blood Stem Cell Transplantation'}, {'id': 'D011241', 'term': 'Prednisone'}, {'id': 'C407664', 'term': 'deltacortene'}, {'id': 'C036266', 'term': 'prednylidene'}], 'ancestors': [{'id': 'D007106', 'term': 'Immune Sera'}, {'id': 'D000906', 'term': 'Antibodies'}, {'id': 'D007136', 'term': 'Immunoglobulins'}, {'id': 'D007162', 'term': 'Immunoproteins'}, {'id': 'D001798', 'term': 'Blood Proteins'}, {'id': 'D011506', 'term': 'Proteins'}, {'id': 'D000602', 'term': 'Amino Acids, Peptides, and Proteins'}, {'id': 'D012712', 'term': 'Serum Globulins'}, {'id': 'D005916', 'term': 'Globulins'}, {'id': 'D001688', 'term': 'Biological Products'}, {'id': 'D045424', 'term': 'Complex Mixtures'}, {'id': 'D009607', 'term': 'Nitrosourea Compounds'}, {'id': 'D014508', 'term': 'Urea'}, {'id': 'D000577', 'term': 'Amides'}, {'id': 'D009930', 'term': 'Organic Chemicals'}, {'id': 'D009603', 'term': 'Nitroso Compounds'}, {'id': 'D003562', 'term': 'Cytidine'}, {'id': 'D011741', 'term': 'Pyrimidine Nucleosides'}, {'id': 'D011743', 'term': 'Pyrimidines'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D001087', 'term': 'Arabinonucleosides'}, {'id': 'D009705', 'term': 'Nucleosides'}, {'id': 'D009706', 'term': 'Nucleic Acids, Nucleotides, and Nucleosides'}, {'id': 'D011034', 'term': 'Podophyllotoxin'}, {'id': 'D013764', 'term': 'Tetrahydronaphthalenes'}, {'id': 'D009281', 'term': 'Naphthalenes'}, {'id': 'D011084', 'term': 'Polycyclic Aromatic Hydrocarbons'}, {'id': 'D006841', 'term': 'Hydrocarbons, Aromatic'}, {'id': 'D006844', 'term': 'Hydrocarbons, Cyclic'}, {'id': 'D006838', 'term': 'Hydrocarbons'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D005960', 'term': 'Glucosides'}, {'id': 'D006027', 'term': 'Glycosides'}, {'id': 'D002241', 'term': 'Carbohydrates'}, {'id': 'D009588', 'term': 'Nitrogen Mustard Compounds'}, {'id': 'D009150', 'term': 'Mustard Compounds'}, {'id': 'D006846', 'term': 'Hydrocarbons, Halogenated'}, {'id': 'D010649', 'term': 'Phenylalanine'}, {'id': 'D024322', 'term': 'Amino Acids, Aromatic'}, {'id': 'D000598', 'term': 'Amino Acids, Cyclic'}, {'id': 'D000596', 'term': 'Amino Acids'}, {'id': 'D018380', 'term': 'Hematopoietic Stem Cell Transplantation'}, {'id': 'D033581', 'term': 'Stem Cell Transplantation'}, {'id': 'D017690', 'term': 'Cell Transplantation'}, {'id': 'D064987', 'term': 'Cell- and Tissue-Based Therapy'}, {'id': 'D001691', 'term': 'Biological Therapy'}, {'id': 'D013812', 'term': 'Therapeutics'}, {'id': 'D014180', 'term': 'Transplantation'}, {'id': 'D013514', 'term': 'Surgical Procedures, Operative'}, {'id': 'D011244', 'term': 'Pregnadienediols'}, {'id': 'D011245', 'term': 'Pregnadienes'}, {'id': 'D011278', 'term': 'Pregnanes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 53}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2008-06'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-07', 'completionDateStruct': {'date': '2030-01-31', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-07-14', 'studyFirstSubmitDate': '2008-07-15', 'studyFirstSubmitQcDate': '2008-07-15', 'lastUpdatePostDateStruct': {'date': '2025-07-16', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2008-07-16', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2025-12-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Incidence of grades 4-5 regimen-related toxicity', 'timeFrame': 'Up to 1 year post-transplant', 'description': 'Assessed by the Regimen Related Toxicity Scale. Using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0. The development of a grade 4 to 5 toxicity of any of the included major organ systems within the first 365 days after transplant will be defined as regimen-related toxicity.'}], 'secondaryOutcomes': [{'measure': 'Transplant-related mortality', 'timeFrame': 'Within 100 days post-transplant', 'description': 'Defined as death within the first 100 days of transplant due to transplant-related complications.'}, {'measure': 'Disease responses', 'timeFrame': 'Up to 5 years', 'description': 'Assessed by clinical, laboratory and radiologic evaluation'}, {'measure': 'Engraftment kinetics', 'timeFrame': 'Over first 60 days post-transplant', 'description': 'Monitored for engraftment kinetics of granulocytes, platelets and red cells post-transplant.'}, {'measure': 'Number of subjects achieving greater than or equal to 4.0 x 10^6 CD34+ cells/kg, after up to two peripheral blood stem cell mobilizations', 'timeFrame': 'Baseline to post mobilization, assessed up to 20 days after starting final mobilization (up to two mobilizations)', 'description': 'Efficacy of peripheral blood stem cell mobilization as evaluated by total number of harvested CD34+cells/kg, for autologous transplant.'}, {'measure': 'Number of subjects with an exacerbation of autoimmune disease symptoms secondary to G-CSF (filgrastim) during peripheral blood stem cell mobilization', 'timeFrame': 'Baseline to post mobilization, assessed up to 20 days after starting final mobilization (up to two mobilizations)', 'description': 'Subjects are evaluated by standardized clinical neurologic tests specific to autoimmune disease type.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['neurologic autoimmune disease', 'autologous transplant autoimmune', 'multiple sclerosis transplant', 'MS stem cell transplant', 'multiple sclerosis stem cell transplant', 'Stiff Person Syndrome', 'HCT for neurologic autoimmune disorders', 'CIDP transplant', 'myasthenia gravis transplant'], 'conditions': ['Autoimmune Disease', 'Neurologic Autoimmune Disease', 'Autologous Transplant Autoimmune', 'Multiple Sclerosis Transplant', 'MS Stem Cell Transplant', 'Multiple Sclerosis Stem Cell Transplant', 'Stiff Person Syndrome', 'HCT for Neurologic Autoimmune Disorders', 'CIDP Transplant', 'Myasthenia Gravis Transplant', 'Autoimmune Nervous System Disorder', 'Central Nervous System Vasculitis', 'Cerebellar Degeneration', 'Chronic Inflammatory Demyelinating Polyneuropathy', 'Lambert Eaton Myasthenic Syndrome', 'Myasthenia Gravis', 'Neuromyelitis Optica', 'Opsoclonus Myoclonus Syndrome', 'Rasmussen Subacute Encephalitis']}, 'descriptionModule': {'briefSummary': "This phase II trial studies the side effects and how well carmustine, etoposide, cytarabine and melphalan together with antithymocyte globulin before a stem cell transplant works in treating patients with autoimmune neurologic disease that did not respond to previous therapy. In autoimmune neurological diseases, the patient's own immune system 'attacks' the nervous system which might include the brain/spinal cord and/or the peripheral nerves. Giving high-dose chemotherapy, including carmustine, etoposide, cytarabine, melphalan, and antithymocyte globulin, before a stem cell transplant weakens the immune system and may help stop the immune system from 'attacking' a patient's nervous system. When the patient's own (autologous) stem cells are infused into the patient they help the bone marrow make red blood cells, white blood cells, and platelets so the blood counts can improve.", 'detailedDescription': 'OUTLINE:\n\nPatients receive carmustine intravenously (IV) on day -6, etoposide IV and cytarabine IV twice daily (BID) on days -5 to -2, melphalan IV on day -1, and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic stem cell transplant on day 0. Patients also receive prednisone orally (PO) once daily (QD) on days 7-21, followed by 2 week taper.\n\nAfter completion of study treatment, patients are followed up at 3 months, 1 year, and then annually thereafter for up to 5 years.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'maximumAge': '71 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Patients with an autoimmune disorder of the central or peripheral nervous system will be eligible; this will include:\n\n * Primary Central Nervous System (CNS) vasculitis\n * Rasmussen's encephalitis\n * Autoimmune peripheral neuropathy (anti-Hu \\[Anna-1\\], anti-GM1 \\[GD1b\\], anti-MAG, anti-ganglioside, anti-sulfatide)\n * Autoimmune cerebellar degeneration\n * Gait Ataxia with Late age Onset Polyneuropathy (GALOP)\n * Stiff Person Syndrome\n * Chronic Inflammatory Demyelinating Polyneuropathy\n * Myasthenia Gravis\n * Lambert-Eaton myasthenic syndrome\n * Human T-cell lymphotropic virus (HTLV)-1-associated myelopathy (HAM) / tropical spastic paraparesis (TSP)\n * Opsoclonus/myoclonus (anti-Ri)\n * Neuromyelitis optica\n * Multiple sclerosis\n * Other central or peripheral nervous system autoimmune diseases as approved by study neurologists and the Fred Hutchinson Cancer Research Center (FHCRC) faculty at Patient Care Conference (PCC)\n* Patients must satisfy the criteria for a diagnosis of one of the severe neurological autoimmune disorders outlined\n* Patients age =\\< 70 years\n* Evidence of disease activity as outlined (e.g. gadolinium enhancement on magnetic resonance imaging of the brain or clinical progression)\n* Patients must have failed at least 2 lines of standard therapy as outlined for the specific diseases\n* DONOR: Sibling of any patient enrolled on this protocol proven by ABO typing, human leukocyte antigen (HLA) typing and variable number tandem repeat (VNTR) analysis to be syngeneic with the patient (e.g. identical twin)\n* DONOR: Willing to undergo multiple apheresis procedures (except donors \\< 12 years who will undergo bone marrow harvests)\n\nExclusion Criteria:\n\n* Age \\>= 71 years\n* Pregnancy or expressed plans to become pregnant within 1 year of the procedure\n* Patients who are serologically positive for human immunodeficiency virus (HIV)\n* Patients with pulmonary, cardiac, hepatic or renal impairment that would limit their ability to receive cytoreductive therapy and compromise their survival; this should include patients with any of the following:\n\n * Severe pulmonary dysfunction associated with a carbon monoxide diffusing capacity (DLCO) (corrected for hemoglobin) \\< 60%, or requires supplemental oxygen; patients who are unable to perform pulmonary function test (because of underlying disease) will be excluded if the oxygen saturation is \\< 92% on room air\n * Uncontrolled malignant arrhythmias, or clinical evidence of congestive heart failure (New York class III-IV) or ejection fraction \\< 50%\n * Renal disease with estimated glomerular filtration rate (GFR) by creatinine clearance or iothalamate clearance \\< 50 ml/min/1.73 m\\^2 body surface area\n * Serum glutamate pyruvate transaminase (SGPT)/aspartate aminotransferase (AST) \\> 3 times normal or direct bilirubin greater than 2.5 mg/dL on two repeated tests\n* Active uncontrolled infection\n* Demonstrated lack of compliance with prior medical care\n* Patients whose life expectancy is limited by illness other than their neurological condition\n* Patients with evidence of myelodysplasia\n* Active malignancy (excluding localized squamous cell or basal cell carcinoma of the skin)\n* DONOR: Inadequate documentation that donor and recipient are syngeneic\n* DONOR: Donors who do not fulfill criteria as apheresis donors as established by institutional guidelines\n* DONOR: Concordant for autoimmune neurological disease(s) as determined by neurological evaluation"}, 'identificationModule': {'nctId': 'NCT00716066', 'briefTitle': 'Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases', 'organization': {'class': 'OTHER', 'fullName': 'Fred Hutchinson Cancer Center'}, 'officialTitle': 'High-Dose Immunosuppressive Therapy Using Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) + Thymoglobulin Followed by Syngeneic or Autologous Hematopoietic Cell Transplantation for Patients With Autoimmune Neurologic Diseases', 'orgStudyIdInfo': {'id': '2260.00'}, 'secondaryIdInfos': [{'id': 'NCI-2010-00403', 'type': 'REGISTRY', 'domain': 'CTRP (Clinical Trial Reporting Program)'}, {'id': '2260.00', 'type': 'OTHER', 'domain': 'Fred Hutch/University of Washington Cancer Consortium'}, {'id': 'RG9213030', 'type': 'OTHER', 'domain': 'Fred Hutch/University of Washington Cancer Consortium'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Treatment (immunosuppressive therapy followed by transplant)', 'description': 'Patients receive carmustine IV on day -6, etoposide IV and cytarabine IV BID on days -5 to -2, melphalan IV on day -1 and antithymocyte globulin IV on days -2 and -1. Patients then undergo autologous or syngeneic stem cell transplant on day 0. Patients also receive prednisone PO QD on days 7-21, followed by 2 week taper.', 'interventionNames': ['Biological: Anti-Thymocyte Globulin', 'Procedure: Autologous Hematopoietic Stem Cell Transplantation', 'Drug: Carmustine', 'Drug: Cytarabine', 'Drug: Etoposide', 'Other: Laboratory Biomarker Analysis', 'Drug: Melphalan', 'Procedure: Peripheral Blood Stem Cell Transplantation', 'Drug: Prednisone', 'Procedure: Syngeneic Bone Marrow Transplantation']}], 'interventions': [{'name': 'Anti-Thymocyte Globulin', 'type': 'BIOLOGICAL', 'otherNames': ['Antithymocyte Globulin', 'Antithymocyte Serum', 'ATG', 'ATGAM', 'ATS', 'Thymoglobulin'], 'description': 'Given IV', 'armGroupLabels': ['Treatment (immunosuppressive therapy followed by transplant)']}, {'name': 'Autologous Hematopoietic Stem Cell Transplantation', 'type': 'PROCEDURE', 'otherNames': ['Autologous Stem Cell Transplantation'], 'description': 'Undergo autologous or syngeneic stem cell transplantation', 'armGroupLabels': ['Treatment (immunosuppressive therapy followed by transplant)']}, {'name': 'Carmustine', 'type': 'DRUG', 'otherNames': ['BCNU', 'Becenum', 'Becenun', 'BiCNU', 'Bis(chloroethyl) Nitrosourea', 'Bis-Chloronitrosourea', 'Carmubris', 'Carmustin', 'Carmustinum', 'FDA 0345', 'Gliadel', "N,N'-Bis(2-chloroethyl)-N-nitrosourea", 'Nitrourean', 'Nitrumon', 'SK 27702', 'SRI 1720', 'WR-139021', '154-93-8'], 'description': 'Given IV', 'armGroupLabels': ['Treatment (immunosuppressive therapy followed by transplant)']}, {'name': 'Cytarabine', 'type': 'DRUG', 'otherNames': ['.beta.-Cytosine arabinoside', '1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-.beta.-D-Arabinofuranosylcytosine', '1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone', '1-Beta-D-arabinofuranosylcytosine', '1.beta.-D-Arabinofuranosylcytosine', '2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-', '2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-', 'Alexan', 'Ara-C', 'ARA-cell', 'Arabine', 'Arabinofuranosylcytosine', 'Arabinosylcytosine', 'Aracytidine', 'Aracytin', 'Aracytine', 'Beta-Cytosine Arabinoside', 'CHX-3311', 'Cytarabinum', 'Cytarbel', 'Cytosar', 'Cytosar-U', 'Cytosine Arabinoside', 'Cytosine-.beta.-arabinoside', 'Cytosine-beta-arabinoside', 'Erpalfa', 'Starasid', 'Tarabine PFS', 'U 19920', 'U-19920', 'Udicil', 'WR-28453', '147-94-4'], 'description': 'Given IV', 'armGroupLabels': ['Treatment (immunosuppressive therapy followed by transplant)']}, {'name': 'Etoposide', 'type': 'DRUG', 'otherNames': ['Demethyl Epipodophyllotoxin Ethylidine Glucoside', 'EPEG', 'Lastet', 'Toposar', 'Vepesid', 'VP 16-213', 'VP-16', 'VP-16-213', '33419-42-0'], 'description': 'Given IV', 'armGroupLabels': ['Treatment (immunosuppressive therapy followed by transplant)']}, {'name': 'Laboratory Biomarker Analysis', 'type': 'OTHER', 'description': 'Correlative studies', 'armGroupLabels': ['Treatment (immunosuppressive therapy followed by transplant)']}, {'name': 'Melphalan', 'type': 'DRUG', 'otherNames': ['Alanine Nitrogen Mustard', 'CB-3025', 'L-PAM', 'L-Phenylalanine Mustard', 'L-Sarcolysin', 'L-Sarcolysin Phenylalanine mustard', 'L-Sarcolysine', 'Melphalanum', 'Phenylalanine Mustard', 'Phenylalanine Nitrogen Mustard', 'Sarcoclorin', 'Sarkolysin', 'WR-19813', '148-82-3'], 'description': 'Given IV', 'armGroupLabels': ['Treatment (immunosuppressive therapy followed by transplant)']}, {'name': 'Peripheral Blood Stem Cell Transplantation', 'type': 'PROCEDURE', 'otherNames': ['PBPC transplantation', 'Peripheral Blood Progenitor Cell Transplantation', 'Peripheral Stem Cell Support', 'Peripheral Stem Cell Transplantation'], 'description': 'Undergo autologous or syngeneic stem cell transplantation', 'armGroupLabels': ['Treatment (immunosuppressive therapy followed by transplant)']}, {'name': 'Prednisone', 'type': 'DRUG', 'otherNames': ['.delta.1-Cortisone', '1, 2-Dehydrocortisone', 'Adasone', 'Cortancyl', 'Dacortin', 'DeCortin', 'Decortisyl', 'Decorton', 'Delta 1-Cortisone', 'Delta-Dome', 'Deltacortene', 'Deltacortisone', 'Deltadehydrocortisone', 'Deltasone', 'Deltison', 'Deltra', 'Econosone', 'Lisacort', 'Meprosona-F', 'Metacortandracin', 'Meticorten', 'Ofisolona', 'Orasone', 'Panafcort', 'Panasol-S', 'Paracort', 'PRED', 'Predicor', 'Predicorten', 'Prednicen-M', 'Prednicort', 'Prednidib', 'Prednilonga', 'Predniment', 'Prednisonum', 'Prednitone', 'Promifen', 'Servisone', 'SK-Prednisone', '53-03-2'], 'description': 'Given PO', 'armGroupLabels': ['Treatment (immunosuppressive therapy followed by transplant)']}, {'name': 'Syngeneic Bone Marrow Transplantation', 'type': 'PROCEDURE', 'description': 'Undergo syngeneic bone marrow transplantation', 'armGroupLabels': ['Treatment (immunosuppressive therapy followed by transplant)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '80218', 'city': 'Denver', 'state': 'Colorado', 'country': 'United States', 'facility': 'Colorado Blood Cancer Institute', 'geoPoint': {'lat': 39.73915, 'lon': -104.9847}}, {'zip': '98109', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Fred Hutch/University of Washington Cancer Consortium', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}, {'zip': '98122-4307', 'city': 'Seattle', 'state': 'Washington', 'country': 'United States', 'facility': 'Swedish Medical Center-First Hill', 'geoPoint': {'lat': 47.60621, 'lon': -122.33207}}], 'overallOfficials': [{'name': 'Leona Holmberg', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Fred Hutch/University of Washington Cancer Consortium'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fred Hutchinson Cancer Center', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}